CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

TherapeuticsMD, Inc.

TXMD
$25MMicro Cap

Next catalyst

Phase 3November 2026

GS1191-0445 injection

Hemophilia A

Get an email about TXMD's next catalysts

Track TherapeuticsMD (TXMD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 14 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

15 upcoming, 3 past

Phase 3Next

GS1191-0445 injection Phase 3 Est. Readout

November 2026~GS1191-0445 injection50

Estimated primary completion for GS1191-0445 injection trial (NCT06833983) in Hemophilia A. Topline data typically follows completion by weeks to months.

Source
Phase 2

RNK08954 Phase 2 Est. Readout

November 2026~RNK0895460

Estimated primary completion for RNK08954 trial (NCT07303465) in KRAS G12D Mutations. Topline data typically follows completion by weeks to months.

Source
Phase 2

TH9619 Phase 2 Est. Readout

December 2026~TH961943

Estimated primary completion for TH9619 trial (NCT07151040) in Solid Tumor. Topline data typically follows completion by weeks to months.

Source
Phase 2

YL201 for Injection Phase 2 Est. Readout

February 2027~YL201 for Injection100

Estimated primary completion for YL201 for Injection trial (NCT06241846) in Metastatic Castration-resistant Prostate Cancer (mCRPC). Topline data typically follows completion by weeks to months.

Source
Phase 2

ALT-100 mAb Phase 2 Est. Readout

Q2 2027~QALT-100 mAb15

Estimated primary completion for ALT-100 mAb trial (NCT05938036) in Acute Respiratory Distress Syndrome (ARDS). Topline data typically follows completion by weeks to months.

Source
Phase 3

Leriglitazone Phase 3 Est. Readout

May 2027~Leriglitazone40

Estimated primary completion for Leriglitazone trial (NCT05819866) in Cerebral Adrenoleukodystrophy (cALD). Topline data typically follows completion by weeks to months.

Source
Phase 3

Veverimer Phase 3 Est. Readout

June 2027~Veverimer150

Estimated primary completion for Veverimer trial (NCT07355062) in CKD. Topline data typically follows completion by weeks to months.

Source
Phase 2

CT3001 Phase 2 Est. Readout

Q2 2027~QCT300178

Estimated primary completion for CT3001 trial (NCT06598007) in Solid Tumor, Adult. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaBOCA RATON1 employees
Drug Pipeline

ELA026

Phase 3

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

arbaclofen

Phase 3

Fragile X Syndrome

AXS-05

Phase 3

Agitation in Patients With Dementia of the Alzheimer's Type

Human platelets

Phase 3

Cardiac Surgery

DaxibotulinumtoxinA for injection

Phase 3

Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

histrelin acetate

Phase 3

Prostate Cancer

Frovatriptan

Phase 3

Menstrually Associated Migraine

CR845

Phase 3

Uremic Pruritus

Plozasiran

Phase 3

Familial Chylomicronemia Syndrome

Oral Calcitonin Tablets

Phase 3

Osteoporosis, Postmenopausal

BHV-7000

Phase 3

Focal Epilepsy

BGF MDI

Phase 3

COPD

Fasedienol Nasal Spray

Phase 3

Social Anxiety Disorder

AC-170

Phase 3

Allergic Conjunctivitis

Scopolamine Nasal Gel

Phase 3

Motion Sickness

EN3835

Phase 3

Adhesive Capsulitis

pagoclone

Phase 3

Stuttering

AXS-05 (dextromethorphan-bupropion)

Phase 3

Agitation in Patients With Dementia of the Alzheimer's Type

Single-Dose IV Oritavancin Diphosphate

Phase 3

Wound Infection

GFF MDI (PT003)

Phase 3

COPD

Neridronate

Phase 3

Complex Regional Pain Syndrome Type I

bempedoic acid

Phase 3

Hypercholesterolemia

Eribulin

Phase 3

Locally Advanced or Metastatic Breast Cancer

ACER-002 (celiprolol)

Phase 3

Vascular Ehlers-Danlos Syndrome

Estradiol

Phase 3

Menopause

Oxymorphone Extended Release

Phase 3

Chronic Pain

Veverimer

Phase 3

CKD

Factor VIII (rFVIIIFc)

Phase 3

Severe Hemophilia A

DPI-386 Nasal Gel

Phase 3

Motion Sickness, Space

Triamcinolone Acetonide

Phase 3

Osteoarthritis of the Knee

Progesterone

Phase 3

Menopause

Xanomeline and Trospium Chloride Capsules

Phase 3

Schizophrenia

BFF MDI

Phase 3

Chronic Obstructive Pulmonary Disorder

AA4500

Phase 3

Peyronie's Disease

BFF MDI (PT009)

Phase 3

Chronic Obstructive Pulmonary Disorder

Lorecivivint

Phase 3

Knee Osteoarthritis

Ublituximab

Phase 3

Relapsing Remitting Multiple Sclerosis

FMX103 minocycline foam

Phase 3

Facial Papulopustular Rosacea

XIAFLEX/XIAPEX

Phase 3

Dupuytren's Contracture

Zelpultide alfa

Phase 3

Bronchopulmonary Dysplasia

oxymorphone HCl

Phase 3

Post Operative Pain

anamorelin HCl

Phase 3

Carcinoma, Non-Small-Cell Lung

GP MDI (PT001)

Phase 3

Chronic Obstructive Pulmonary Disease (COPD)

Dalbavancin

Phase 3

Abscess

Valrubicin

Phase 3

Carcinoma in Situ

000-0551 Lotion

Phase 3

Plaque Psoriasis

Topical SM04554 solution

Phase 3

Androgenetic Alopecia

RBT-1

Phase 3

Post-Operative Complications in Cardiac Surgery

Pegtibatinase

Phase 3

Homocystinuria

AR101 powder provided in capsules & sachets

Phase 3

Peanut Allergy

REL-1017

Phase 3

Major Depressive Disorder

A-101 Solution

Phase 3

Seborrheic Keratosis

Dexycu

Phase 3

Inflammation

Difluprednate Ophthalmic Emulsion

Phase 3

Inflammation

YL201

Phase 3

Advanced Esophageal Squamous Cell Carcinoma

Nirogacestat oral tablet

Phase 3

Desmoid Tumor

MST-188

Phase 3

Vaso-occlusive Crisis

Reproxalap Ophthalmic

Phase 3

Dry Eye

Moxifloxacin

Phase 3

Community Acquired Bacterial Pneumonia

188-0551 Spray

Phase 3

Plaque Psoriasis

XAF5 (concentration A:)

Phase 3

Steatoblepharon

PTX-022

Phase 3

Pachyonychia Congenita

BGF MDI (PT010)

Phase 3

COPD

ETC-1002

Phase 3

Hypercholesterolemia

BHV-1300

Phase 3

Graves Disease

Loncastuximab Tesirine

Phase 3

Relapsed Diffuse Large B-Cell Lymphoma

delafloxacin

Phase 3

Skin and Subcutaneous Tissue Bacterial Infections

Radiprodil

Phase 3

GRIN-related Neurodevelopmental Disorder

Testosterone

Phase 3

Hypogonadism

Nefecon

Phase 3

Primary IgA Nephropathy

Prednisolone Acetate

Phase 3

Uveitis

Botulinum Toxins, Type A

Phase 3

Glabellar Frown Lines

AR101

Phase 3

Peanut Allergy

Teriflunomide

Phase 3

Relapsing Multiple Sclerosis (RMS)

Triamcinolone Hexacetonide

Phase 3

Knee Osteoarthritis

Solriamfetol

Phase 3

Major Depressive Disorder

Brepocitinib PO QD

Phase 3

Uveitis, Posterior

Androxal

Phase 3

Secondary Hypogonadism

Linsitinib

Phase 3

Thyroid Eye Disease

ADX-102 Ophthalmic

Phase 3

Non-infectious Anterior Uveitis

Collagenase clostridium histolyticum

Phase 3

Dupuytren's Disease

enclomiphene citrate

Phase 3

Effect of Treatment on Bone Mineral Density

Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler

Phase 3

COPD

Saroglitazar magnesium

Phase 3

Non-Alcoholic Fatty Liver Disease

FMX101

Phase 3

Acne Vulgaris

Tiratricol

Phase 3

Monocarboxylate Transporter 8 Deficiency

Meropenem-Vaborbactam

Phase 3

Urinary Tract Infection Complicated

AXS-07 (MoSEIC meloxicam and rizatriptan)

Phase 3

Migraine

KarXT

Phase 3

Psychosis Associated With Alzheimer's Disease

Pimicotinib(ABSK021)

Phase 3

Tenosynovial Giant Cell Tumor

Oral Brepocitinib

Phase 3

Cutaneous Sarcoidosis

cyclosporine

Phase 3

Dry Eye Syndromes

Leriglitazone

Phase 3

Cerebral Adrenoleukodystrophy (cALD)

Oxymorphone immediate release

Phase 3

Acute Pain

intranasal carbetocin

Phase 3

Prader-Willi Syndrome

Scopolamine

Phase 3

Motion Sickness

Difluprednate

Phase 3

Inflammation

YL202

Phase 3

Non-Small Cell Lung Cancer

JDP-205 Injection

Phase 3

Acute Urticaria

GS1191-0445 injection

Phase 3

Hemophilia A

oral estradiol

Phase 3

Menopause

PRO 2000/5

Phase 3

HIV Infections

oral progesterone

Phase 3

Menopause

EFB0027 (metformin delayed release)

Phase 2

Type 2 Diabetes Mellitus

H-1337

Phase 2

Glaucoma Open-Angle Primary

Usnoflast

Phase 2

Amyotrophic Lateral Sclerosis (ALS)

hI-con1

Phase 2

Choroidal Neovascularization

BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)

Phase 2

Colorectal Cancer

Rhu-pGSN

Phase 2

Acute Respiratory Distress Syndrome

MIN-102

Phase 2

Friedreich Ataxia

ET140203 T Cells

Phase 2

Hepatoblastoma

INT131 besylate

Phase 2

Type 2 Diabetes Mellitus

FP01

Phase 2

Acute Cough

TST001

Phase 2

Advanced Cancer

pegylated IFNa2b

Phase 2

Hepatitis C

Linezolid

Phase 2

Skin and Subcutaneous Tissue Bacterial Infections

Tranilast

Phase 2

Gout

GKT137831

Phase 2

Type 2 Diabetes Mellitus With Diabetic Nephropathy

ABT-301

Phase 2

Colorectal Cancer (Diagnosis)

VB10.16

Phase 2

HPV Positive Oropharyngeal Squamous Cell Carcinoma

AdVEGFXC1

Phase 2

Coronary Artery Disease

ST-100 Ophthalmic Solution

Phase 2

Dry Eye Disease

RT001 (Botulinum Toxin Type A Topical Gel)

Phase 2

Lateral Canthal Lines

JTX-8064

Phase 2

Cancer

NAP (Naptumomab estafenatox)

Phase 2

Non-small Cell Lung Cancer

Ipamorelin

Phase 2

Gastrointestinal Dysmotility

Testosterone undecanoate

Phase 2

Hypogonadism

CB-03-01

Phase 2

Acne Vulgaris

SOC (mTOR + CNI)

Phase 2

Kidney Transplantation

VK2735

Phase 2

Weight Loss

Latanoprost

Phase 2

Open-Angle Glaucoma

ECT204 T cells

Phase 2

Hepatocellular Carcinoma

RIST4721

Phase 2

Palmoplantar Pustulosis

TG-0054 combined with G-CSF

Phase 2

Multiple Myeloma

RNK05047

Phase 2

Advanced Solid Tumor

SRSD107

Phase 2

Coronary Artery Disease (CAD)

PER-001 Intravitreal Implant - Low Dose

Phase 2

Diabetic Retinopathy

Proellex

Phase 2

Uterine Fibroids

RNK08954

Phase 2

KRAS G12D Mutations

DAXXIFY

Phase 2

Glabellar Frown Lines

JCARH125

Phase 2

Multiple Myeloma

pTTL

Phase 2

Colorectal Cancer

SM04554

Phase 2

Androgenetic Alopecia

AT-007

Phase 2

Classic Galactosemia

TT-034

Phase 2

Hepatitis C

EHT102 Injection

Phase 2

Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Radezolid

Phase 2

Community-Acquired Pneumonia (CAP)

RZL-012+Lidacaine injection prior treatment

Phase 2

Submental Fat

ACER-801

Phase 2

Post-menopausal Vasomotor Symptoms

Bone marrow mesenchymal stem cells

Phase 2

Osteoarthritis, Knee

TH9619

Phase 2

Solid Tumor

ABT-101

Phase 2

Advanced Solid Tumor

RNK08954-01

Phase 2

KRAS G12D Mutation

ST-01

Phase 2

Chronic Pain

Cenicriviroc

Phase 2

HIV-1 Infection

Telapristone Acetate

Phase 2

Uterine Fibroids

BIO-106

Phase 2

Advanced Cancer

Latanoprost Punctal Plug Delivery System

Phase 2

Ocular Hypertension

Lidoderm

Phase 2

Osteoarthritis, Knee

Glycopyrronium MDI

Phase 2

Asthma

AVZO-1418

Phase 2

Solid Tumor Cancer

Aglatimagene besadenovec

Phase 2

Borderline Resectable Pancreatic Adenocarcinoma

EL219

Phase 2

Invasive Mould Infection

AMT-116

Phase 2

Advanced Solid Tumors

AC-150 Combo

Phase 2

Allergic Conjunctivitis

TNP-2092 capsules

Phase 2

Hyperammonemia

Camidanlumab Tesirine

Phase 2

Relapsed Hodgkin Lymphoma

Met DR

Phase 2

Type 2 Diabetes Mellitus

Active

Phase 2

Asthma

PRTX007

Phase 2

Melanoma Stage III

AXS-12 (Reboxetine)

Phase 2

Narcolepsy

PTX-200

Phase 2

Acute Leukemia

Oral rsCT tablet

Phase 2

Phase 1 Pharmacodynamic Study

AFNT-211

Phase 2

Pancreatic Ductal Adenocarcinoma

RM-131

Phase 2

Constipation

Triac

Phase 2

Allan-Herndon-Dudley Syndrome

CTI-1601

Phase 2

Friedreich Ataxia

Inhaled PT001

Phase 2

Chronic Obstructive Pulmonary Disease

ABSK061 + ABSK043

Phase 2

HER2-Gastric/Gastroesophageal Junction Cancer

AVZO-021

Phase 2

Advanced Solid Tumor

QTORIN rapamycin anhydrous

Phase 2

Cutaneous Venous Malformations

ABSK-011+BSC

Phase 2

Hepatocellular Carcinoma (HCC)

NVG-2089

Phase 2

Immune Thrombocytopenia (ITP)

NPT 2042

Phase 2

Epilepsy, Generalized

MGCD0103

Phase 2

Lymphoma

FT-2102

Phase 2

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)

MAA868 Cohort 1

Phase 2

Atrial Fibrillation

Nexagon® Low Dose

Phase 2

Venous Leg Ulcers

BC-819/PEI

Phase 2

Superficial Bladder Cancer

VLS-1488

Phase 2

Advanced Solid Tumor

NDV-3A

Phase 2

Vulvovaginal Candidiasis

octreotide acetate

Phase 2

Acromegaly

RAP-219

Phase 2

Focal Epilepsy

VDA-1102

Phase 2

Actinic Keratosis

UHE-101 Cream

Phase 2

Acne Vulgaris

Faldaprevir

Phase 2

Hepatitis C Viral Infection

ATI-450

Phase 2

Hidradenitis Suppurativa

PTG-300

Phase 2

Polycythemia Vera

TDM-105795

Phase 2

Alopecia, Androgenetic

MSDC-0602K

Phase 2

Non-alcoholic Fatty Liver Disease

Allo-QuadCAR01-T

Phase 2

Lymphoma Diffuse Large B-cell

188-0551 Solution

Phase 2

Plaque Psoriasis

IG3018

Phase 2

Hyperuricemia

YL201 for Injection

Phase 2

Advanced Solid Tumor

Serlopitant

Phase 2

Pruritus

Halobetasol Propionate Lotion

Phase 2

Psoriasis

OPN-305

Phase 2

Myelodysplastic Syndrome

Gene Therapy product:vMCO-I

Phase 2

Retinitis Pigmentosa

GFH018

Phase 2

NSCLC, Stage III

Sevuparin

Phase 2

Sickle-Cell Disease

voretigene neparvovec-rzyl

Phase 2

Leber Congenital Amaurosis

SRP1020

Phase 2

Advanced Solid Tumors

Gene Therapy Product-MCO-010

Phase 2

Retinitis Pigmentosa

Oral Testosterone Undecanoate

Phase 2

Hypogonadism

UHE-105

Phase 2

Scalp Psoriasis

Recombinant Human Plasma Gelsolin

Phase 2

Community-acquired Pneumonia

NT100

Phase 2

Repeated IVF Failure

XOPH5 Ointment

Phase 2

Lower Eyelid Steatoblepharon (Excess Eyelid Fat)

fludarabine phosphate

Phase 2

Accelerated Phase Chronic Myelogenous Leukemia

ABSK043 in combination with Glecirasib

Phase 2

Non-Small Cell Lung Cancer

PT-112

Phase 2

Non-Small Cell Lung Cancer (NSCLC)

ABSK043 in combination with Firmonertinib

Phase 2

Non-Small Cell Lung Cancer With EGFR Mutation

trospium chloride inhalation powder (TrIP)

Phase 2

Chronic Obstructive Pulmonary Disease

SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)

Phase 2

Adult Brain Glioblastoma

Brepocitinib

Phase 2

Dermatomyositis

DAXI

Phase 2

Plantar Fasciitis

Norketotifen

Phase 2

Allergic Rhinitis

LT3001 Drug Product

Phase 2

Acute Ischemic Stroke

ABX-002

Phase 2

Major Depressive Disorder

ETX-018810

Phase 2

Diabetic Peripheral Neuropathic Pain

ALT-100 mAb

Phase 2

Acute Respiratory Distress Syndrome (ARDS)

CT-868

Phase 2

Obesity

RT001 Botulinum toxin type A (Dose A)

Phase 2

Lateral Canthal Lines

AHB-137

Phase 2

Hepatitis B, Chronic

ANG003 Dose A

Phase 2

Exocrine Pancreatic Insufficiency (EPI)

SF0166 Topical Ophthalmic Solution

Phase 2

Age-Related Macular Degeneration

Eteplirsen

Phase 2

Muscular Dystrophy, Duchenne

Etavopivat

Phase 2

Sickle Cell Disease

ADX-629

Phase 2

Chronic Cough

BTRX-246040

Phase 2

Parkinson Disease

IMC-001

Phase 2

Extranodal NK/T-cell Lymphoma, Nasal Type

Enicepatide

Phase 2

Obesity

ARD-101

Phase 2

Bariatric Surgery

CCH-aaes

Phase 2

Edematous Fibrosclerotic Panniculopathy

SM04690

Phase 2

Osteoarthritis

VSA006

Phase 2

Nash

HG004

Phase 2

Leber Congenital Amaurosis

Tagraxofusp

Phase 2

Acute Myeloid Leukemia

Bemarituzumab

Phase 2

Gastric Cancer

AZD2115 Dose 1

Phase 2

Chronic Obstructive Pulmonary Disease (COPD)

INT-210 Capsule

Phase 2

Ulcerative Colitis (UC)

SKP-1041 (experimental formulation of zaleplon)

Phase 2

Sleep Disorder

CT3001

Phase 2

Solid Tumor, Adult

CT041

Phase 2

Gastric Cancer

Saroglitazar

Phase 2

Liver Transplant; Complications

JPI-547

Phase 2

Pancreatic Ductal Adenocarcinoma

Solabegron immediate release tablets, low dose

Phase 2

Overactive Bladder

Varenicline tartrate

Phase 2

Trigeminal Neuralgia

RZL-012

Phase 2

Submental Fat

T3D-959

Phase 2

Alzheimer Disease

Solabegron modified release tablets, low dose

Phase 2

Overactive Bladder

RT001

Phase 2

Lateral Canthal Lines

Trivalent ganglioside vaccine

Phase 2

Sarcoma

PT005 MDI

Phase 2

Chronic Obstructive Pulmonary Disease

PTI-808

Phase 2

Healthy Volunteer - Complete

Oral testosterone undecanoate (containing T)

Phase 2

Male Hypogonadism

TD-6450

Phase 2

Hepatitis C Viral Infection

VAL-083, Dianhydrogalactitol

Phase 2

Glioma

Mocetinostat

Phase 2

Urothelial Carcinoma

YL202 should be intravenously infused

Phase 2

NSCLC

NFX-179 gel

Phase 2

Cutaneous Neurofibroma

LM103 TILs Injection

Phase 2

Non-Small Cell Lung Cancer

PT001 MDI

Phase 2

Chronic Obstructive Pulmonary Disease

YL242

Phase 2

Advanced Solid Tumor

dotinurad

Phase 2

Gout

Orvepitant Maleate

Phase 2

Chronic Refractory Cough

botulinum toxin, Type A

Phase 2

Lateral Canthal Lines

CQSS2

Phase 2

Smoking Cessation

ETX-19477

Phase 2

Advanced or Metastatic Solid Tumors

Latanoprost-PPDS

Phase 2

Glaucoma

2B3-101

Phase 2

Brain Metastases

TG-0054

Phase 2

Multiple Myeloma

FT-2102 (olutasidenib)

Phase 2

Acute Myeloid Leukemia

CTS3497

Phase 2

Solid Tumor

Gene Therapy-vMCO-010

Phase 2

Stargardt Disease

A-101

Phase 2

Seborrheic Keratosis

Naproxen sodium

Phase 2

Gastric Ulcer

LY2940094

Phase 2

Alcoholism

lisocabtagene maraleucel

Phase 2

Lymphoma, Non-Hodgkin

TNP-2092 for injection

Phase 2

Periprosthetic Joint Infection (PJI)

AVZO-103

Phase 2

Solid Tumor Cancer

NMRA-335140

Phase 2

Major Depressive Disorder

JP-1366

Phase 2

GERD

T0903131 Besylate

Phase 2

Diabetes Mellitus, Type II

hPSC-CM Therapy

Phase 2

Heart Failure

SLS-002

Phase 2

Depressive Disorder, Major

Botulinum Toxin Type A

Phase 2

Glabellar Frown Lines

Setanaxib

Phase 2

Alport Syndrome

Frequently asked questions

What is in TherapeuticsMD, Inc.'s drug pipeline?→

CatalystAlert tracks 298 drug candidates in TherapeuticsMD, Inc.'s (TXMD) pipeline across Phase 3, Phase 2. Its lead program is GS1191-0445 injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is TherapeuticsMD, Inc.'s next FDA catalyst?→

TherapeuticsMD, Inc.'s (TXMD) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TXMD biotech catalysts?→

Add TXMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TherapeuticsMD, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply